- Trials with a EudraCT protocol (338)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (8)
338 result(s) found for: Clinical significance.
Displaying page 1 of 17.
EudraCT Number: 2011-004879-36 | Sponsor Protocol Number: 100450 | Start Date*: 2015-05-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: Comparative study of the immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-DNA Hepatitis B vaccine (10µg) with or without Hepatitis B immunoglobulin (HBIG) in newborns of H... | ||
Medical condition: Vaccination of healthy newborns of HBsAg+ and/or HBeAg+ mothers against Hepatitis. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-002629-23 | Sponsor Protocol Number: 100449 | Start Date*: 2015-05-22 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: Immunogenicity and protective efficacy of GlaxoSmithKline Biologicals’ rec-Hepatitis B vaccine (10 µg) in newborns of Hepa-titis B envelope antigen positive (HBeAg+) and Hepatitis B surface antigen... | ||
Medical condition: Hepatitis B vaccination in healthy newborns of HBeAg+ and HBsAg+ mothers | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2005-001745-42 | Sponsor Protocol Number: 3045 | Start Date*: 2005-12-06 |
Sponsor Name:University of Liverpool and Royal Liverpool University Hospital | ||
Full Title: BCR-ABL Peptide Vaccination in Normal Subjects.An investigation in normal subjects with HLA-A3 and HLA-B8, as an extension of an identical study in patients with Chronic Myeloid Leukaemia. | ||
Medical condition: Healthy Subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-008713-20 | Sponsor Protocol Number: BGC20-1531-04 | Start Date*: 2009-03-26 |
Sponsor Name:Danish Headache Center | ||
Full Title: EP4 receptor antagonism and PGE2 in a human headache model | ||
Medical condition: PGE2 will induce headache in healthy subjects and BGC20-1531 or placebo will be used to block the developement of headache. In the future BGC20-1531 might be a possible anti-migraine drug. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-001877-94 | Sponsor Protocol Number: COX-2I | Start Date*: 2012-09-17 |
Sponsor Name:UNIVERSITY CLINIC GOLNIK | ||
Full Title: Significance of COX-2 inhibition in first line treatment of extensive disease small-cell lung cancer (ED-SCLC) | ||
Medical condition: extensive disease small-cell lung cancer (ED-SCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-006731-45 | Sponsor Protocol Number: PB-2006-01 | Start Date*: 2007-04-26 |
Sponsor Name:Køge Sygehus | ||
Full Title: PPI-Rebound-Trial | ||
Medical condition: This is a healthy volunteer trial designed to investigate if long-term treatment with nexium is the cause of a clinically significant acid rebound phenomenon. The intended indication for nexium is ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001259-39 | Sponsor Protocol Number: RWGRD2005-09 | Start Date*: 2005-06-30 |
Sponsor Name:West Herts NHS Trust | ||
Full Title: An investigation into a novel clinical use of a single low dose of insulin in the prevention of excessive cutaneous scarring | ||
Medical condition: Normal scarring Hypertrophic scarring Hypertrophic scarring | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-005022-10 | Sponsor Protocol Number: SYN-1748-MAL-0030-I | Start Date*: 2018-02-13 | ||||||||||||||||
Sponsor Name:Technische Universität München, Fakultät für Medizin | ||||||||||||||||||
Full Title: Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | ||||||||||||||||||
Medical condition: Noonan Syndrom and Neurofibromatosis Type 1 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000966-12 | Sponsor Protocol Number: 12/0419 | Start Date*: 2016-08-20 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Autologous Stem Cells in Achilles Tendinopathy (ASCAT)- A phase II, single centre, proof of concept study | |||||||||||||
Medical condition: The Achilles tendon is the largest tendon in the body and it plays an important role in the biomechanics of the lower extremity.The disease to be studied in the trial is Achilles tendinopathy (AT).... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003686-36 | Sponsor Protocol Number: AR13001 | Start Date*: 2021-07-19 |
Sponsor Name:Finnish Defence Forces | ||
Full Title: Immune response to SARS-CoV-2 vaccines and its clinical significance in the Finnish Defence Forces | ||
Medical condition: Immune response induced by SARS-CoV-2 vaccination. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002130-23 | Sponsor Protocol Number: TQLnephrectomi_v_1 | Start Date*: 2017-07-28 |
Sponsor Name:Zealand university hospital Roskilde | ||
Full Title: Ultrasoundguided Transmuscular Quadratus Lumborum(TQL) block for hand assisted laparoscopic nephrectomy - a randomized controlled trial | ||
Medical condition: The postoperative pain after Hand assisted lap.nephrectomy operation.Our one year retrospective study of patients with Kidney cancer treated with Hand assisted lap.nephrectomy revealed that, 71% of... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002480-26 | Sponsor Protocol Number: CACZ885V2301 | Start Date*: 2018-12-03 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subje... | |||||||||||||
Medical condition: Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) DE (Completed) FR (Completed) ES (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) HU (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005549-46 | Sponsor Protocol Number: TS-005-DK | Start Date*: 2009-01-21 | |||||||||||
Sponsor Name:Hvidovre Hospital | |||||||||||||
Full Title: A randomised, controlled prospective open parallel groups clinical trial for the evaluation of efficacy and safety of TachoSil® in women undergoing hysterectomy. A pilot study | |||||||||||||
Medical condition: It is the intention with this clinical trial to evaluate wheter TachoSil may reduce the formation of postoperative haematomas on the vaginal cuff following hysterectomi. The presence of a postopera... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002142-13 | Sponsor Protocol Number: P06241/P202 | Start Date*: 2012-05-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp | |||||||||||||
Full Title: A 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of Mometasone Furoate/Formoterol Fumarate MDI Fixed Dose Combination Versus Mometasone Furoate MDI Monotherapy in ... | |||||||||||||
Medical condition: Persistent Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) EE (Completed) CZ (Completed) LV (Completed) GB (Completed) ES (Completed) DE (Completed) IE (Completed) SK (Completed) PL (Completed) IT (Completed) BG (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002767-17 | Sponsor Protocol Number: D0816C00020 | Start Date*: 2017-12-14 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Pa... | |||||||||||||
Medical condition: Non Germline BRCA Mutated Ovarian Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) SI (Completed) BG (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) AT (Completed) SE (Completed) PT (Completed) NO (Completed) DK (Completed) FI (Completed) PL (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005022-31 | Sponsor Protocol Number: AI424-172 | Start Date*: 2006-01-31 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: Effect of a High-Fat or a Light Meal Relative to Fasting Conditions on the Pharmacokinetics of Atazanavir when Administered with Ritonavir in Healthy Subjects | ||
Medical condition: Healthy subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004432-70 | Sponsor Protocol Number: ema1-profilC-2006 | Start Date*: 2006-12-04 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | |||||||||||||
Full Title: A multicenter phase II study to evaluate the safety, tolerability and efficacy of caspofungin as prophylactic treatment of invasive fungal infections in patients with acute leukemia undergoing ind... | |||||||||||||
Medical condition: neutropenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003321-29 | Sponsor Protocol Number: 17-169 | Start Date*: Information not available in EudraCT |
Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty | ||
Full Title: Clinical relevance of the antimicrobial resistance testing in the treatment of chronic wounds with antiseptics | ||
Medical condition: Decubitus, acute or chronic wounds (open wounds existing ≥ 14 days) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-000023-15 | Sponsor Protocol Number: H7T-MC-TAAL | Start Date*: 2005-02-10 | |||||||||||
Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
Full Title: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects who are to Undergo Percutaneous Coronary Intervention | |||||||||||||
Medical condition: Reduction of atherothrombotic events in patients with acute coronary syndromes (ACS) that is patients with ST-segment elevation MI [STEMI], non-ST-segment elevation MI [NSTEMI], or unstable angina... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) AT (Completed) FI (Completed) HU (Completed) CZ (Completed) SK (Completed) DE (Completed) IT (Completed) LT (Completed) EE (Completed) LV (Completed) IS (Completed) ES (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003117-41 | Sponsor Protocol Number: CAIN457D2204 | Start Date*: 2012-02-03 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma ... | |||||||||||||
Medical condition: Asthma not adequately controlled with inhaled corticosteroids and long acting beta-agonists | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
